Daptomycin

达托霉素

Report date: 2022/01/14 13:23:58
NMEFirst In Class

Base Information

Drug NameDaptomycin
Drug Alias NameDaptomicina达帕托霉素DaptomycineDaptomycinumCubicin +[12] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Lipopeptide antibiotics
Mechanisms of ActionCell wall inhibitors
TargetsNot applicable
Therapy Area/IndicationsComplicated Skin and Soft Tissue InfectionsInfective EndocarditisSolid tumours +[24] 
Global Approved IndicationsComplicated Skin and Soft Tissue InfectionsInfective EndocarditisStaphylococcal Infections +[6] 
Approved Indications in ChinaStaphylococcal InfectionsBacteremiaBacterial Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2003/09/12
Country/TerritoryUnited StatesRussian FederationGermany +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme CorpCubist Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncMerck Sharp & Dohme CorpMerck Sharp & Dohme Bv +[6] 
Inactive CompaniesUniversity of ZurichUniversity Of RochesterOhsu Knight Cancer Institute +[11] 
Active IndicationsComplicated Skin and Soft Tissue InfectionsInfective EndocarditisStaphylococcal Infections +[6] 
Inactive IndicationsSolid tumoursHot FlashesFever +[18] 

Other Information

ATC CodeJ01XX09
Related LinksWikipediaDrugBankKEGG